Since one mechanism of resistance to the anti-tumor effects of vemurafenib is the mutational or growth factor-induced activation of RAS [23, 24], concurrent administration of BRAF inhibitors and 17-AAG might conceivably delay the growth of resistant clones of melanoma cells in patients with BRAFV600E melanomas. Here, BRAF is linked to melanoma.